Name: Liang Zong, MD, Ph.D (Tokyo University), Post-Doctor(Harvard Medical School), Current Position: Vice President, Changzhi People's Hospital; Professor, Department of Surgery, Changzhi People's Hospital; Professor, Department of The Cancer Center for Precision & Translation Medicine, Changzhi People's Hospital. I recently sequenced two thousand pair of of gastric cancers from multiple Chinese populations, and submit part of data to Nature (Mutational landscape and genetic feature of gastric adenocarcinoma in multiple Chinese ethnicities). In this study, we identified a novel subtype of gastric cancer, and made a summary as follows. Gastric cancer is a heterogeneous malignancy and the fifth most common cancer worldwide, with 44% of cases occurring in China. Elucidation of genetic subtypes may improve gastric cancer treatment planning. Matched tumour and peritumoural (non-malignant gastric mucosa) tissue samples were collected from 306 Chinese patients and subjected to whole-exome sequencing (WES). The results were used to produce a Chinese Gastric Cancer Genome Atlas (CGCGA). Patients from nine Chinese ethnic groups (Han, Zhuang, Hui, Uygur, Yi, Tibetan, Mongolian, Bai, and Kazakh), representing 95% of the Chinese population were included. Systematic comparison of CGCGA data with TCGA (The Cancer Genome Atlas) data, in which 437 gastric cancer cases are represented, showed that genomic alteration signatures in the present cohort differed markedly from those reported for Western cohorts. Dr. Liang Zong, as a Japanese Government Scholarship winner (Monbukagakusho: MEXT), entered University of Tokyo for his Ph.D. Degree in April 2013. At the end of 2014, he was honored to receive Grand Prize of Research Award from University of Tokyo. In 2015, he wined a First Prize in the thesis defense of University of Tokyo. In 2017 March, he graduated from the University of Tokyo. Till now he, as the first author or corresponding author, published 70 SCI papers, e.g. Lancet, Journal of Clinical Oncology, Oncogene, Gastric Cancer and so on. These papers were cited 1379 times. Also, he, as a co-author, joined the writing of a book named Precision Medicine in China which was published by Science. In 2019, he won the third Prize of Future Scientist in 2019 Chinese Gastric Cancer Congress. H-index:20. Dr. Liang Zong has reviewed over 50 manuscripts for JAMA Network Open, International Journal of Surgery, Cancer letters, Gastric Cancer, World Journal of Gastroenterology and so on. Dr. Liang Zong aims to draw the multi-omic landscape of Chinese gastric adenocarcinoma. Dr. Liang Zong owns a communication skill to cooperation with a lot of experts to conduct several multi-center studies. Dr. Liang Zong has a great interest to identify the mechanism of gastric carcinoma for Chinese multi nationalities.